• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Iranian Journal of Pharmaceutical Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 18 (2019)
Volume Volume 17 (2018)
Issue Special Issue 2
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Special Issue 1
Issue Issue 1
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Yazdi, A., Mokhtarzadeh Khanghahi, A., Baharvand, H., Javan, M. (2018). Fingolimod Enhances Oligodendrocyte Differentiation of Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitors. Iranian Journal of Pharmaceutical Research, 17(4), 1444-1457. doi: 10.22037/ijpr.2018.2310
Azadeh Yazdi; Akram Mokhtarzadeh Khanghahi; Hossein Baharvand; Mohammad Javan. "Fingolimod Enhances Oligodendrocyte Differentiation of Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitors". Iranian Journal of Pharmaceutical Research, 17, 4, 2018, 1444-1457. doi: 10.22037/ijpr.2018.2310
Yazdi, A., Mokhtarzadeh Khanghahi, A., Baharvand, H., Javan, M. (2018). 'Fingolimod Enhances Oligodendrocyte Differentiation of Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitors', Iranian Journal of Pharmaceutical Research, 17(4), pp. 1444-1457. doi: 10.22037/ijpr.2018.2310
Yazdi, A., Mokhtarzadeh Khanghahi, A., Baharvand, H., Javan, M. Fingolimod Enhances Oligodendrocyte Differentiation of Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitors. Iranian Journal of Pharmaceutical Research, 2018; 17(4): 1444-1457. doi: 10.22037/ijpr.2018.2310

Fingolimod Enhances Oligodendrocyte Differentiation of Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitors

Article 28, Volume 17, Issue 4, Autumn 2018, Page 1444-1457  XML PDF (6.93 MB)
Document Type: Research article
DOI: 10.22037/ijpr.2018.2310
Authors
Azadeh Yazdiorcid 1; Akram Mokhtarzadeh Khanghahi2; Hossein Baharvand2, 3; Mohammad Javan email 4, 2
1Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2Department of Brain Sciences and Cognition, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
3Department of Developmental Biology, University of Science and Culture, Tehran, Iran.
4Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract
Multiple sclerosis (MS) is an autoimmune disease which affects myelin in the central nervous system (CNS) and leads to serious disability. Currently available treatments for MS mainly suppress the immune system. Regenerative medicine-based approaches attempt to increase myelin repair by targeting endogenous progenitors or transplanting stem cells or their derivatives. Fingolimod exerts anti-inflammatory effects and directly affects neural cells. In this study we assessed the effect of fingolimod on transplanted human induced pluripotent stem cell derived neural progenitors (hiPSC-NPs). hiPSC-NPs were labeled by green fluorescence protein (GFP) and transplanted into the corpus callosum of mice which were chronically demyelinated after cuprizone (CPZ) feedings for 10 weeks. The animals received fingolimod from 1 day prior to NPs transplantation via gavage as well as daily intraperitoneal cyclosporine A from 2 days before cell transplantation until the time of sampling. At either 7 or 21 days after NPs transplantation, the animals were sacrificed and their brains were histologically evaluated for the number of transplanted cells and their fate. In the animals treated with fingolimod, we observed higher numbers of NPs within the injection site compared to the animals who did not receive fingolimod showing that hiPSC- NPs were more efficiently differentiated to the oligodendrocyte lineage. These data have suggested that repetitive treatment with fingolimod, beside its anti-inflammatory effect, may enhance the survival and differentiation of transplanted NPs to oligodendrocyte lineage cells to participate in myelin repair.

Keywords
Fingolimod (FTY720); Cell therapy; Neural progenitor cell; Cuprizone; Oligodendrocyte; Mouse
Main Subjects
toxicology and Pharmacology
Statistics
Article View: 217
PDF Download: 396
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Statistics

Journal Management System. Designed by sinaweb.